Terms: = Ovarian cancer AND CTCF, P49711, 10664, ENSG00000102974 AND Treatment
4 results:
1. RPL35A drives ovarian cancer progression by promoting the binding of YY1 to ctcf promoter.
Wu H; Xia L; Sun L; Li D; Liu X; Song H; Sheng J; Wang K; Feng Q
J Cell Mol Med; 2024 Mar; 28(6):e18115. PubMed ID: 38436544
[TBL] [Abstract] [Full Text] [Related]
2. ctcfL regulates the PI3K-Akt pathway and it is a target for personalized ovarian cancer therapy.
Salgado-Albarrán M; Späth J; González-Barrios R; Baumbach J; Soto-Reyes E
NPJ Syst Biol Appl; 2022 Feb; 8(1):5. PubMed ID: 35132075
[TBL] [Abstract] [Full Text] [Related]
3. BORIS (ctcfL) is not expressed in most human breast cell lines and high grade breast carcinomas.
Hines WC; Bazarov AV; Mukhopadhyay R; Yaswen P
PLoS One; 2010 Mar; 5(3):e9738. PubMed ID: 20305816
[TBL] [Abstract] [Full Text] [Related]
4. DNA methylation-dependent regulation of BORIS/ctcfL expression in ovarian cancer.
Woloszynska-Read A; James SR; Link PA; Yu J; Odunsi K; Karpf AR
Cancer Immun; 2007 Dec; 7():21. PubMed ID: 18095639
[TBL] [Abstract] [Full Text] [Related]
